Baykara M, Yaman M, Buyukberber S, Tufan G, Demirci U, Benekli M, Coskun U, Ozet A, Umit Bagriacik E
Sakarya University Training and Research Hospital, Department of Medical Oncology, Sakarya, Turkey.
J BUON. 2013 Oct-Dec;18(4):921-7.
To investigate the relationship of the apoptosis regulators X-linked inhibitor of apoptosis (XIAP) and ubiquitin specific protease 8 (USP8) with clinical parameters, survival and response to chemotherapy in patients with advanced stages of non-small cell lung cancer (NSCLC).
The study included 34 NSCLC patients (28 females, 6 males) and 44 healthy individuals (17 males, 27 females) as a control group. XIAP and USP8 levels were determined by ELISA.
The median serum XIAP level of the patients and the control group showed no significant difference. USP8 level was higher in patients than in controls (p<0.0001). In univariate analysis, there was no significant relationship between XIAP and USP8 serum levels and age, sex, performance status, weight loss, stage of disease, histopatological type and response to chemotherapy. Response to chemotherapy did not differ between the high and low XIAP and USP8 groups . There was no significant difference in progression- free survival (PFS) (p=0.432 and p=0.50, respectively) and overall survival (OS) (p=0.989 and p=0.90, respectively) between the low and high XIAP and USP8 groups.
No relationship was found in serum XIAP and USP8 levels with clinical parameters, response to chemotherapy, PFS and OS in patients with advanced stages of NSCLC.
探讨凋亡调节因子X连锁凋亡抑制蛋白（XIAP）和泛素特异性蛋白酶8（USP8）与晚期非小细胞肺癌（NSCLC）患者临床参数、生存率及化疗反应之间的关系。
本研究纳入34例NSCLC患者（28例女性，6例男性），并以44例健康个体（17例男性，27例女性）作为对照组。采用酶联免疫吸附测定法（ELISA）测定XIAP和USP8水平。
患者组和对照组的血清XIAP水平中位数无显著差异。患者组的USP8水平高于对照组（p<0.0001）。单因素分析显示，XIAP和USP8血清水平与年龄、性别、体能状态、体重减轻、疾病分期、组织病理学类型及化疗反应之间无显著关系。XIAP和USP8高低水平组之间的化疗反应无差异。XIAP和USP8高低水平组之间的无进展生存期（PFS）（分别为p=0.432和p=0.50）和总生存期（OS）（分别为p=0.989和p=0.90）无显著差异。
在晚期NSCLC患者中，未发现血清XIAP和USP8水平与临床参数、化疗反应、PFS及OS之间存在关联。
